Showing 3251-3260 of 4063 results for "".
- Gentex Acquires eSighthttps://modernod.com/news/gentex-acquires-esight/2482048/Gentex announced the asset acquisition of eSight, a provider of vision enhancement technologies, to develop and manufacture next-generation mobile electronic eyewear that is designed to help people living with visual impairments. The company will feature eSight’s technology at CES 2024, the
- Claris Bio Advances Corneal Healing Product Candidate; Secures New Fundinghttps://modernod.com/news/claris-bio-developer-of-corneal-healing-product-candidate-names-new-investor/2482042/Claris Bio unveiled the company and its lead program with a total of $57 million invested. Claris, initially funded in 2020, is developing recombinant human variant hepatocyte growth factor, dHGF, to accelerate and improve the quality of corneal healing in patients with corneal eye dise
- Iridex Confirms Medicare Administrative Contractors Retired Local Coverage Determinations that Restricted Cyclophotocoagulationhttps://modernod.com/news/iridex-confirms-medicare-administrative-contractors-retired-local-coverage-determinations-that-restricted-cyclophotocoagulation/2482036/Iridex announced all five Medicare Administrative Contractors (MACs) retired their local coverage determinations (LCDs) that were scheduled to take effect on January 29, 2024. Iridex and other stakeholders opposing the LCDs have engaged with the MACs throughout the comment period to advocate
- Regeneron Wins Patent Case to Extend Eylea Protectionhttps://modernod.com/news/regeneron-wins-patent-case-to-extend-eylea-protection/2482035/A West Virginia judge ruled that Viatris' proposed biosimilar violates a Regeneron patent that covers ophthalmic formulations of Eylea, according to news reports. The patent is expected to expire in June 2027.
- Ashley Magargee Named CEO of Genentechhttps://modernod.com/news/genentech-names-ashley-magargee-as-ceo/2482008/Ashley Magargee has been appointed Chief Executive Officer (CEO) of Genentech, effective January 1, 2024. In addition to her role as Head of US Commercial Portfolio, Ms. Magargee has been serving as ad interim CEO since the departure of Alexander Hardy on November 1, 2023. She will repo
- National Eye Institute Selects Richard Lee, MD, PhD, as Clinical Directorhttps://modernod.com/news/national-eye-institute-selects-richard-lee-md-phd-as-clinical-director/2481999/The National Eye Institute (NEI) has chosen Richard Lee, MD, PhD, as the institute’s clinical director, overseeing clinical research and serving as clinical policy advisor for NEI. Dr. Lee comes to NEI from Moorfields Eye Hospital, where he’s had several roles since 2011, th
- Ocuphire Pharma Appoints Joseph K. Schachle COOhttps://modernod.com/news/ocuphire-pharma-reports-inducement-grant-for-new-coo/2481985/Ocuphire Pharma announced that the independent members of its Board of Directors approved an equity award under the company’s 2021 Inducement Plan as a material inducement to Joseph K. Schachle in connection with his employment with Ocuphire effective on November 27, 2023. The equity award
- Pixium Vision Receives Takeover Offerhttps://modernod.com/news/pixium-vision-receives-takeover-offer/2481976/Pixium Vision, whose safeguard proceedings were converted into receivership by the Paris Commercial Court on November 13, 2023, announced that the court-appointed administrators have received a takeover offer for the assets and activities of Pixium. The name of the a
- Keeler USA and Long Grove Pharmaceuticals Enter Distribution Agreement for AK-FLUORhttps://modernod.com/news/keeler-usa-long-grove-pharmaceuticals-enter-into-a-distribution-agreement-for-ak-fluor/2481972/Keeler has announced a partnership with Long Grove Pharmaceuticals to distribute AK-FLUOR (fluorescein injection), which is indicated for diagnostic fluorescein angiography. Long Grove Pharmaceuticals was established in 2019 by Water Street Healthcare Partners,
- Regenxbio Presents New Data on Investigational AAV Therapeutic for Retinal Conditionshttps://modernod.com/news/regenxbio-presents-new-data-on-investigational-aav-therapeutic-at-aao/2481967/At the American Academy of Ophthalmology 2023 Annual Meeting in San Francisco, new data was presented for Regenxbio's ABBV-RGX-314, an investigational one-time AAV therapeutic being developed in collaboration with AbbVie for the treatment of wet age-related macular degener